Evidence map›Paper›PMID 41583252›Full record

ArticleCureus2025

A Rare Case of Non-cirrhotic Hepatocellular Carcinoma in a Female Adolescent: Diagnostic and Multimodal Treatment Challenges in a Low-Resource Setting.

Yatrasana Singh, Barry Raghunanan, Ravi Maharaj

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yatrasana SinghGeneral Surgery, University of the West Indies, St. Augustine Campus, Champ Fleurs, TTO.
Barry RaghunananSurgery, University of the West Indies, St. Augustine Campus, Champ Fleurs, TTO.
Ravi MaharajSurgery, University of the West Indies, St. Augustine Campus, Champ Fleurs, TTO.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is rare in children and adolescents, particularly in non-cirrhotic livers. Pediatric HCC often presents with aggressive behaviour and requires individualized, multidisciplinary care. Liver transplantation is a potential curative option, but this procedure is not readily accessible in many regions. In this case, a 15-year-old female patient presented with vague right-sided abdominal pain, fatigue, and abdominal distension. Imaging revealed a large heterogeneous hepatic mass with right portal vein thrombosis and mass effect on the inferior vena cava. Laboratory investigations revealed elevated transaminases and negative viral hepatitis markers. Histology was suggestive of HCC with possible hepatoblastoma features. Despite the tumour's size potentially qualifying her for a liver transplant according to the Milan and University of California, San Francisco criteria, we opted for neoadjuvant chemotherapy and a resectional approach due to inherent limitations. She underwent four cycles of neoadjuvant sorafenib-based chemotherapy, followed by extended right hepatectomy and right hemi-diaphragmatic resection. A postoperative bile duct injury was successfully managed with the endoscopic retrograde cholangiopancreatography rendezvous technique for biliary stenting. In settings without readily accessible transplant capability, aggressive multimodal therapy including neoadjuvant chemotherapy and liver resection can offer curative potential. This case highlights the importance of adapting treatment strategies to available resources while maintaining oncologic intent.

Indexed as

hepatoblasomahepatocellular carcinoma (hcc)non-cirrhotic hepatocellularright hepatectomysorafenib

Identifiers

PMID41583252
PMCPMC12825689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.